» Articles » PMID: 32775366

The Clinical Application of Mesenchymal Stem Cells in Liver Disease: the Current Situation and Potential Future

Overview
Journal Ann Transl Med
Date 2020 Aug 11
PMID 32775366
Citations 26
Authors
Affiliations
Soon will be listed here.
Abstract

Liver disease is a major health issue which present poor clinical treatment performance. Cirrhosis and liver failure are common clinical manifestations of liver diseases. Liver transplantation is recognized as the ultimate and most efficient therapy to the end stage of liver disease. But it was limited by the shortage of honor organs and high cost. Nowadays, stem cell therapy gained more and more attention due to its attractive efficacy in treating liver disease especially in cirrhosis during the clinical trials. Mesenchymal stem cell (MSC) can be differentiated into hepatocytes, promote liver regeneration, inhibit liver fibrosis and induce liver apoptosis, particularly via paracrine mechanisms. This review will highlight recent clinical applications of MSC, providing the available evidence and discussing some unsolved questions in treating liver disease.

Citing Articles

Preclinical Evaluation of the Safety, Toxicity and Efficacy of Genetically Modified Wharton's Jelly Mesenchymal Stem/Stromal Cells Expressing the Antimicrobial Peptide SE-33.

Gasanov V, Kashirskikh D, Khotina V, Kuzmina D, Nikitochkina S, Mukhina I Cells. 2025; 14(5).

PMID: 40072070 PMC: 11898551. DOI: 10.3390/cells14050341.


Human Liver MSCs Retain Their Basic Cellular Properties in Chronically Inflamed Liver Tissue.

Kim Y, Lupatov A, Burunova V, Bagmet N, Chardarov N, Malov S Int J Mol Sci. 2025; 25(24.

PMID: 39769138 PMC: 11676302. DOI: 10.3390/ijms252413374.


Mesenchymal stem cell therapy as a game-changer in liver diseases: review of current clinical trials.

Huang W, Li Y, Chen P, Ma K, Wang L Stem Cell Res Ther. 2025; 16(1):3.

PMID: 39762946 PMC: 11705688. DOI: 10.1186/s13287-024-04127-y.


Unraveling the Exosome-miR-133a Axis: Targeting TGF-β Signaling via WJ-MSC-Derived Exosomes for Anti-Fibrotic Therapy in Liver Fibrosis.

Saki S, Monjezi S, Ghaffari F, Orak G, Salehipour Bavarsad S, Khedri A Iran Biomed J. 2024; 28(5 & 6):235-44.

PMID: 39629623 PMC: 11829155. DOI: 10.61186/ibj.4357.


Role of Olive Leaf Extract, Mesenchymal Stem Cells or Low Radiation Dose in Alleviating Hepatic Injury in Rats.

Gharib O, Fahmy H, Abdou F Dose Response. 2024; 22(3):15593258241289301.

PMID: 39483141 PMC: 11526167. DOI: 10.1177/15593258241289301.


References
1.
Bernal W, Wendon J . Acute liver failure. N Engl J Med. 2013; 369(26):2525-34. DOI: 10.1056/NEJMra1208937. View

2.
Fitzmaurice C, Allen C, Barber R, Barregard L, Bhutta Z, Brenner H . Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-years for 32 Cancer Groups, 1990 to 2015: A Systematic Analysis for the Global Burden of Disease Study. JAMA Oncol. 2016; 3(4):524-548. PMC: 6103527. DOI: 10.1001/jamaoncol.2016.5688. View

3.
El-Shennawy S, Abdel Aaty H, Radwan N, Abdel-Hameed D, Alam-Eldin Y, El-Ashkar A . Therapeutic Potential of Mesenchymal Stem Cells on Early and Late Experimental Hepatic Schistosomiasis Model. J Parasitol. 2015; 101(5):587-97. DOI: 10.1645/15-754.1. View

4.
Mohammadi Gorji S, Karimpor Malekshah A, Hashemi-Soteh M, Rafiei A, Parivar K, Aghdami N . Effect of mesenchymal stem cells on Doxorubicin-induced fibrosis. Cell J. 2013; 14(2):142-51. PMC: 3584430. View

5.
Baksh D, Yao R, Tuan R . Comparison of proliferative and multilineage differentiation potential of human mesenchymal stem cells derived from umbilical cord and bone marrow. Stem Cells. 2007; 25(6):1384-92. DOI: 10.1634/stemcells.2006-0709. View